Health Technology · Pharmaceuticals: Major · NSE: GUJTHEM · data 2026-10-09
Gujarat Themis Biosyn Ltd
Health check: Weak (3.8/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹363.5
Market cap
₹4,787 cr
P/E
81.4
P/B
—
ROE
17.4%
ROCE
18.2%
Debt / equity
0.56
Dividend yield
0.18%
1-year return
-10.7%
52-week high
₹479
52-week low
₹225.05
Operating margin
38.9%
Growth
| Revenue (last 12 months) | ₹174 cr |
| Net profit (last 12 months) | ₹49 cr |
| Sales growth, 3 years (yearly) | 3.8% |
| Profit growth, 3 years (yearly) | -7.0% |
Chart patterns
- Double bottom — forming (key level ₹382.2)
Similar companies
FDC Ltd. (FDC) · Novartis India Limited (NOVARTIND) · RPG Life Sciences Limited (RPGLIFE) · SMS Pharmaceuticals Limited (SMSPHARMA) · Gufic Biosciences Limited (GUFICBIO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open GUJTHEM in NSE Scanner →